Skip to main content

Belantamab mafodotin-blmf

Details of the Drug
Generic Name:
None Available
Drug Type:
B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate
How the Drug is Given:

for injection, for intravenous use

Belantamab mafodotin-blmf

Indications and Usage

Belantamab mafodotin-blmf is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).


Side effects needing medical attention

The most common adverse reactions are keratopathy (corneal epithelium change on eye exam), decreased visual acuity, nausea, blurred vision, fever (pyrexia), infusion-related reactions, and fatigue.


See full prescribing information for complete boxed warning.

  • Blenrep caused changes in the corneal epithelium resulting in changes in vision, including severe vision loss and corneal ulcer, and symptoms, such as blurred vision and dry eyes.
  • Conduct ophthalmic exams at baseline, prior to each dose, and promptly for worsening symptoms. Withhold BLENREP until improvement and resume, or permanently discontinue, based on severity.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.